235 related articles for article (PubMed ID: 20943209)
21. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
[TBL] [Abstract][Full Text] [Related]
22. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
Siberry GK; Warshaw MG; Williams PL; Spector SA; Decker MD; Jean-Philippe P; Yogev R; Heckman BE; Manzella A; Roa J; Nachman S; Lujan-Zilbermann J;
Pediatr Infect Dis J; 2012 Jan; 31(1):47-52. PubMed ID: 21987006
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
Halperin SA; Diaz-Mitoma F; Dull P; Anemona A; Ceddia F
Eur J Clin Microbiol Infect Dis; 2010 Mar; 29(3):259-67. PubMed ID: 20033465
[TBL] [Abstract][Full Text] [Related]
26. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial.
Block SL; Shepard J; Garfield H; Xie F; Han L; Dull PM; Smolenov I
Pediatr Infect Dis J; 2016 Feb; 35(2):e48-59. PubMed ID: 26479973
[TBL] [Abstract][Full Text] [Related]
28. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
Black S; Klein NP; Shah J; Bedell L; Karsten A; Dull PM
Vaccine; 2010 Jan; 28(3):657-63. PubMed ID: 19895922
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.
Gasparini R; Conversano M; Bona G; Gabutti G; Anemona A; Dull PM; Ceddia F
Clin Vaccine Immunol; 2010 Apr; 17(4):537-44. PubMed ID: 20164251
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
Tregnaghi M; Lopez P; Stamboulian D; Graña G; Odrljin T; Bedell L; Dull PM
Int J Infect Dis; 2014 Sep; 26():22-30. PubMed ID: 24980467
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
[TBL] [Abstract][Full Text] [Related]
37. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
Cooper B; DeTora L; Stoddard J
Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
[TBL] [Abstract][Full Text] [Related]
38. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.
Pichichero M; Casey J; Blatter M; Rothstein E; Ryall R; Bybel M; Gilmet G; Papa T
Pediatr Infect Dis J; 2005 Jan; 24(1):57-62. PubMed ID: 15665711
[TBL] [Abstract][Full Text] [Related]
39. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
[TBL] [Abstract][Full Text] [Related]
40. Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.
Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Han L; Smolenov I; Dull P
Pediatr Infect Dis J; 2015 Oct; 34(10):e264-78. PubMed ID: 26135245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
